샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941795

진단용 AI 시장 규모, 점유율, 동향 분석 보고서 : 컴포넌트별, 진단 유형별, 지역별, 부문별 예측(2026-2033년)

Artificial Intelligence In Diagnostics Market Size, Share & Trends Analysis Report By Component, By Diagnosis Type, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

진단용 AI 시장 요약

세계의 진단용 AI 시장 규모는 2025년에 19억 7,000만 달러로 추정되며, 2033년까지 96억 8,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 21.74%를 나타낼 것으로 예측됩니다. 시장 성장의 주요 요인은 머신러닝과 딥러닝의 발전으로 보다 빠르고 정확한 진단 솔루션이 가능해졌기 때문입니다.

종양학, 심장학, 신경학 등의 분야에서는 질병의 조기 발견에 대한 수요 증가로 인해 AI 기술 도입이 확대되고 있습니다. 예를 들어 2024년 2월 Philips는 진단, 중재적 시술, 스크리닝을 위해 설계된 첨단 AI 탑재 CT 시스템 'Philips CT 5300'을 발표했습니다. 이 적응력이 뛰어난 X선 CT 시스템은 진단 정확도를 높이고, 워크플로우를 효율화하며, 시스템 가동률을 최적화합니다.

당뇨병, 암, 심혈관 질환 등 만성질환의 유병률 증가와 조기 및 정확한 진단에 대한 수요 증가가 시장 성장을 촉진하는 주요 요인입니다. 전 세계에서 암 발병률이 증가함에 따라 종양학 분야에서 AI에 대한 의존도가 높아지고 있습니다. 미국 국립보건원(NIH)의 2023년 추정에 따르면 미국에서는 약 200만 명이 암 진단을 받았다고 합니다. 유방암은 가장 많이 진단된 암으로 여성은 약 297,790명, 남성은 약 2,800명으로 추정됩니다. 마찬가지로 질병통제예방센터(CDC)에 따르면 2023년 미국에서 심혈관 질환으로 인해 91만 9,032명이 사망할 것으로 예상되며, 이는 전체 사망자 3명 중 1명이 심혈관 질환으로 사망할 것으로 예측됩니다.

이러한 높은 이환율은 진단 업무의 부담을 증가시킵니다. 의료 IT 인프라의 발전과 클라우드 스토리지, 컴퓨팅, 머신러닝 알고리즘의 지속적인 기술 개발은 AI 탑재 시스템의 진단 통합을 지원하여 효율적이고 정확한 진단을 제공합니다. 이를 통해 의료진은 적시에 적절한 치료 계획을 수립할 수 있습니다. 병리 및 방사선 의학 서비스에서는 AI 기반 알고리즘이 널리 채택되고 있습니다. 예를 들어 2026년 1월 알펜그로우 바이오사이언스와 파스넷은 전립선암과 방광암을 위한 3D AI 진단 검사 개발 및 상용화를 위한 전략적 제휴를 체결한 바 있습니다. 이번 협력을 통해 미국 비뇨기종양학은 2D에서 3D 병리학으로 진화하고, 영상 진단, AI 분석, 워크플로우를 통합하여 정확도를 향상시킬 수 있습니다.

"PathNet의 비뇨기 종양학, 디지털화, AI 분야에서의 리더십과 강력한 전국적 확장 기반은 임상 3D 병리학을 시장에 도입하는 데 있으며, 탁월한 파트너가 될 것입니다. 양사는 협력하여 기존 2D 조직학에서 얻을 수 없는 지식을 제공하는 진단 툴을 구축하고 있습니다. "

알펜그로우 바이오사이언스 CEO 니콜라스 레더(Nicholas Ledger) 박사

또한 만성콩팥병(CKD) 및 신장 기능 검사, 그리고 다양한 만성질환의 진단을 위해 여러 AI 탑재 툴이 활용되고 있습니다. 예를 들어 2024년 5월 프리미어사는 아스트라제네카와 제휴하여 'Uncover CKD-Care Collective' 구상을 시작했습니다. 이 구상은 미진단 CKD 환자를 찾아내고, 의료 프로바이더의 인식을 높이며, 미국 의료 시스템이 CKD의 진단, 치료 및 관리를 개선할 수 있도록 지원하는 것을 목표로 하고 있습니다. 프리미어사의 PINC AI 기술과 서비스 플랫폼을 활용하여 미진단 CKD 증가 추세와 이로 인한 미국 의료시스템의 경제적 부담 경감을 위해 노력할 것입니다.

자주 묻는 질문

  • 진단용 AI 시장 규모는 어떻게 예측되나요?
  • 진단용 AI 시장의 성장 요인은 무엇인가요?
  • AI 기술이 도입되고 있는 주요 분야는 어디인가요?
  • AI 기반 진단 시스템의 발전이 의료진에게 어떤 이점을 제공하나요?
  • 2023년 미국에서 암 진단을 받은 인원은 얼마나 되나요?
  • AI 기술이 만성콩팥병(CKD) 진단에 어떻게 활용되고 있나요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 진단용 AI 시장 변수, 동향, 범위

제4장 진단용 AI 시장 : 컴포넌트별 추정·동향 분석

제5장 진단용 AI 시장 : 진단 유형별 추정·동향 분석

제6장 진단용 AI 시장 : 지역별 추정·동향 분석

제7장 경쟁 구도

KSA

Artificial Intelligence In Diagnostics Market Summary

The global artificial intelligence in diagnostics market size was estimated at USD 1.97 billion in 2025 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 21.74% from 2026 to 2033. Market growth is driven by advancements in machine learning and deep learning, enabling faster, more accurate diagnostic solutions.

In oncology, cardiology, and neurology, among the areas, the growing demand for early disease detection has led to increased adoption of AI technologies. For instance, in February 2024, Royal Philips introduced the Philips CT 5300, an advanced AI-powered CT system designed for diagnostics, interventional procedures, and screenings. The adaptable X-ray CT system enhances diagnostic accuracy, streamlines workflows, and optimizes system availability.

Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, etc., coupled with the increasing demand for early & accurate diagnosis, are significant factors driving market growth. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths.

Such a high prevalence increases the diagnostic workload. Advancements in healthcare IT infrastructure and ongoing technological developments in cloud storage, computing, and machine learning algorithms support the integration of AI-powered systems into diagnostics to provide efficient & accurate diagnoses, allowing care providers to devise timely & appropriate treatment plans. Pathology and radiology services are witnessing a widespread adoption of AI-based algorithms. For instance, in January 2026, Alpenglow Biosciences and PathNet formed a strategic partnership to develop and commercialize 3D AI diagnostic tests for prostate and bladder cancer. The collaboration advances urologic oncology from 2D to 3D pathology in the U.S., integrating imaging, AI analytics, and workflows for enhanced accuracy.

"PathNet's leadership in urologic oncology, digitization, AI, and strong national footprint make them an exceptional partner as we bring clinical 3D pathology to market. Together, we are building diagnostic tools that deliver insights not achievable with conventional 2D histology."

Dr. Nicholas Reder, CEO of Alpenglow Biosciences

In addition, several AI-powered tools are used to diagnose chronic kidney disease (CKD) & kidney function tests, and various chronic diseases. For instance, in May 2024, Premier, Inc. partnered with AstraZeneca to launch the Uncover CKD - Care Collective initiative. The aim is to identify patients with undiagnosed CKD, raise awareness among healthcare providers, and assist U.S. health systems in improving their CKD diagnosis, treatment, and management. Leveraging Premier's PINC AI technology and services platform, the initiative seeks to address the increasing prevalence of undiagnosed CKD and its associated economic burden on the U.S. healthcare system.

Global Artificial Intelligence In Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in diagnostics market report based on component, diagnosis type, and region:

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
  • Hardware
  • Services
  • Diagnosis Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Cardiology
  • Oncology
  • Pathology
  • Radiology
  • Chest and Lung
  • Neurology
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Component
    • 1.1.2. Diagnosis type
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Component outlook
    • 2.2.2. Diagnosis type outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Artificial Intelligence In Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Market opportunity analysis
    • 3.2.4. Market challenges analysis
  • 3.3. Artificial Intelligence In Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
  • 3.4. Case Study Insights

Chapter 4. Artificial Intelligence In Diagnostics Market: Component Estimates & Trend Analysis

  • 4.1. Component Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Artificial Intelligence In Diagnostics Market, By Component Outlook
  • 4.4. Software
    • 4.4.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.5. Hardware
    • 4.5.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Market estimates and forecast, 2021 to 2033 (USD Million)

Chapter 5. Artificial Intelligence In Diagnostics Market: Diagnosis Type Estimates & Trend Analysis

  • 5.1. Diagnosis Type Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Artificial Intelligence In Diagnostics Market, By Diagnosis Type Outlook
  • 5.4. Cardiology
    • 5.4.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.6. Pathology
    • 5.6.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.7. Radiology
    • 5.7.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.8. Chest and Lung
    • 5.8.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.9. Neurology
    • 5.9.1. Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Market estimates and forecast, 2021 to 2033 (USD Million)

Chapter 6. Artificial Intelligence In Diagnostics Market: Regional Estimates & Trend Analysis, By Component, By Diagnosis Type

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Competitor Growth Readiness Index (GRI), 2025
  • 7.2. Competitor Capability Matrix, 2025
  • 7.3. Company Categorization
  • 7.4. Company Market Position Analysis
  • 7.5. Strategy Mapping
  • 7.6. Company Profiles/Listing
    • 7.6.1. Key company market share analysis, 2025
    • 7.6.2. Siemens Healthineers
      • 7.6.2.1. Company overview
      • 7.6.2.2. Financial performance
      • 7.6.2.3. Product benchmarking
      • 7.6.2.4. Strategic initiatives
    • 7.6.3. Zebra Technologies Corp.
      • 7.6.3.1. Company overview
      • 7.6.3.2. Financial performance
      • 7.6.3.3. Product benchmarking
      • 7.6.3.4. Strategic initiatives
    • 7.6.4. Riverain Technologies
      • 7.6.4.1. Company overview
      • 7.6.4.2. Financial performance
      • 7.6.4.3. Product benchmarking
      • 7.6.4.4. Strategic initiatives
    • 7.6.5. Vuno, Inc.
      • 7.6.5.1. Company overview
      • 7.6.5.2. Financial performance
      • 7.6.5.3. Product benchmarking
      • 7.6.5.4. Strategic initiatives
    • 7.6.6. Aidoc
      • 7.6.6.1. Company overview
      • 7.6.6.2. Financial performance
      • 7.6.6.3. Product benchmarking
      • 7.6.6.4. Strategic initiatives
    • 7.6.7. NovaSignal Corporation (previously known as Neural Analytics, acquired by NeuraSignal, Inc.)
      • 7.6.7.1. Company overview
      • 7.6.7.2. Financial performance
      • 7.6.7.3. Product benchmarking
      • 7.6.7.4. Strategic initiatives
    • 7.6.8. Koninklijke Philips N.V.
      • 7.6.8.1. Company overview
      • 7.6.8.2. Financial performance
      • 7.6.8.3. Product benchmarking
      • 7.6.8.4. Strategic initiatives
    • 7.6.9. Digital Diagnostics, Inc.
      • 7.6.9.1. Company overview
      • 7.6.9.2. Financial performance
      • 7.6.9.3. Product benchmarking
      • 7.6.9.4. Strategic initiatives
    • 7.6.10. GE Healthcare
      • 7.6.10.1. Company overview
      • 7.6.10.2. Financial performance
      • 7.6.10.3. Product benchmarking
      • 7.6.10.4. Strategic initiatives
    • 7.6.11. AliveCor Inc.
      • 7.6.11.1. Company overview
      • 7.6.11.2. Financial performance
      • 7.6.11.3. Product benchmarking
      • 7.6.11.4. Strategic initiatives
    • 7.6.12. F. Hoffmann-La Roche Ltd
      • 7.6.12.1. Company overview
      • 7.6.12.2. Financial performance
      • 7.6.12.3. Product benchmarking
      • 7.6.12.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제